Implications of CVD-REAL 2 study for Indian diabetic population
South Asians are reported to have a higher risk of developing macrovascular complications of Diabetes, i.e., coronary artery and cerebrovascular diseases as compared to Caucasians. Literature evidence has shown that among the currently available agents, the sodium/glucose cotransporter 2 inhibitors...
Main Authors: | Rajeev Chawla, Shalini Jaggi |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2019-01-01
|
Series: | Journal of Diabetology |
Subjects: | |
Online Access: | http://www.journalofdiabetology.org/article.asp?issn=2078-7685;year=2019;volume=10;issue=2;spage=57;epage=61;aulast=Chawla |
Similar Items
-
Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin
by: Julio Rosenstock, et al. -
Assessment of dapagliflozin effect on diabetic endothelial dysfunction of brachial artery (ADDENDA-BHS2 trial): rationale, design, and baseline characteristics of a randomized controlled trial
by: Riobaldo M. R. Cintra, et al.
Published: (2019-07-01) -
Efficacy of Body Weight Reduction on the SGLT2 Inhibitor in People with Type 2 Diabetes Mellitus
by: Hyun A Cho, et al.
Published: (2017-06-01) -
High prevalence of genital mycotic infections with sodium-glucose co-transporter 2 inhibitors among Indian patients with type 2 diabetes
by: Ajay Aggarwal, et al.
Published: (2019-01-01) -
Management of Diabetes Associated with Nephrotic Syndrome: Therapeutic Potential of Dapagliflozin for Protracted Volume Retention
by: Toshimi Imai, et al.
Published: (2015-11-01)